RMi Pre-opening: Digestion

May 1, 2026 8:05am

Earnings reactions were somewhat mixed but tech ended positive, industrials surge, yields ease, VIX got crushed while oil was higher, then ending day slightly lower

“Existential' risks are never as existential as markets first think” <Goldman Sachs>

RISK is always a factor remaining below the surface …  boiling-up with shocks of profiteering on upsides shaking but not rocking the C&GT sector!

Earnings: Moderna (MRNA)

Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t!

The end of April trading

Say/write less, mean more …

Thursday’s RMi Closing Bell: Bubblicious … https://www.regmedinvestors.com/articles/14401

I chose to speak-up when many analysts, brokers and commentators have shut-up!

Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.

Thursday: The pre-open Dow futures are UP +0.25% or (+126 points), the S&P futures are UP +0.12% ( +8 points) and the Nasdaq futures are DOWN -0.18% or (-50 points)

• U.S. stock futures inch higher, Friday, May 1
• European equities and bourses rebound as oil prices fall,
• Most major Asian markets were closed due to the May Day holiday; Australia and Japan markets climb, looking past Iran war escalation fears

Economic Data: It’s still all about oil pricing

• 9:45 am                S&P final U.S. manufacturing PMI (final) - April                
• 10:00 am             ISM manufacturing - April           <The business sentiment gauge rose to 52.7 a month ago, marking a 3^rd straight month in expansionary territory (>50). Economists forecast another rise to 53.5 for April>  

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

• Thursday: The Dow closed UP +790.33 points or +1.62%, the S&P closed UP +73.05 points or +1.02% while the Nasdaq closed UP +219.073 points or +0.89%
• Wednesday (my) 40-company covered sector’s advance/decline line opened negative with 4 incliner, 34 decliners and 2 flats, ending with a negative close of 5 incliners, 33 decliners and 2 flats
• Tuesday: The Dow closed DOWN -25.86 points or -0.05%, the S&P closed DOWN -35.08 points or -0.49% while the Nasdaq closed DOWN -223.301 points or -0.90%
• Monday: The Dow closed DOWN -62.92 points or -0.13%, the S&P closed UP +8.83 points or +0.12% while the Nasdaq closed UP +50.502 points or +0.20%
• lastFriday: The Dow closed DOWN -79.61 points or -0.16%, the S&P closed UP +56.68 points or +0.80% while the Nasdaq closed UP +398.094 points or +1.63%

• Last week: The S&P 500 ended +0.5%, the Dow recorded a -0.4% decline and the Nasdaq rose +1.5%.
• The previous week: The S&P gained +3.6%, the Dow +3% and the Nasdaq ascended +4.7
• April so far: The S&P 500 is up more than 9%, while the Nasdaq has surged over 15% and the Dow has gained more than 6%.

Q2/26 – 1 neutral, 10 negative, 9 positive closes and 1 holiday

• Q1 – March – 9 positive and 13 negative closes
• February – 1 market holiday, 11 positive and 8 negative closes
• January – 2 holiday, 2 neutral, 9 negative and 9 positive closes 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

…Dangerous times re share pricing

BioNTech SE (BNTX)

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

I believe jets will be flying this weekend!!

Q1/26 Earnings Release Dates:

• Moderna (MRNA) - Friday, 5/1
• IQVIA Holdings (IQV), uniQure NV (QURE), Ultragenyx Pharmaceuticals (RARE) and Supernus Therapeutics (SUPN) – Tuesday, 5/5
• Sarepta Therapeutics (SRPT) – Wednesday, 5/6
• Vericel (VCEL) – Thursday, 5/7

Welcome to my world of defining the “grey’ in our universe!

• I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
• if I wanted to be liked, I wouldn’t have been an analyst/journalist.

April 5th Week:

• 4/30 – Thursday closed positive with 31 incliners, 6 decliners and 3 flats
• 4/29 - Wednesday closed negative with 5 incliners, 33 decliners and 2 flats
• 4/28 – Tuesday closed negative with 17 incliners, 20 decliners and 3 flats
• 4/27 - Monday closed negative with 13 incliners, 24 decliners and 3 flats

April 4th Week:

• 4/24 – Friday closed negative with 11 incliners, 27 decliners and 2 flats
• 4/23 - Thursday closed negative with 7 incliners, 30 decliners and 3 flats
• 4/22 – Wednesday closed positive with 30 incliners, 9 decliners and 1 flat
• 4/21 – Tuesday closed negative with 5 incliners, 33 decliners and 2 flats
• 4/20 - Monday closed negative with 16 incliners, 21 decliners and 3 flats

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.